WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Anticonvulsant-CMAP-v5, Defined time period starts_concurrent_ with_start_of Seizure occurrence, Potential exacerbation of pre-existing seizures documents Seizure occurrence, Seizure type has_reference_values Partial seizure, Safety Endpoint has Observation or Assessment, Repeated concepts/instances (e.g. Stroke, Death) are denoted by dotted outline, FDA Efficacy Endpoints for Anticonvulsant Therapies has_components Secondary efficacy endpoint, Quality of life in epilepsy documents Clinical Global Impression (CGI), Primary efficacy endpoints (e.g. Seizure frequency) are denoted by bold font, Seizure severity has_pertinent_information Quality of life in epilepsy, Seizure type has_reference_values Generalized seizure, Therapeutic Efficacy Point has Observation or Assessment, Seizure frequency documents Observation time period, Safety Endpoint has Intervention, Primary efficacy endpoint documents Time to first/next seizure, Primary efficacy endpoint documents Seizure frequency, Observation time period is_documented_in Seizure diary, Observation time period starts_concurrent_ with_start_of Intervention, Partial seizure refers_to Partial seizure subtype, FDA Efficacy Endpoints for Anticonvulsant Therapies has_components Primary efficacy endpoint, Seizure count is_documented_in Seizure diary